Tag: Oncology
-
Americans Living Longer After Cancer Diagnosis: A New Era of Survival
Record Rise in Five-Year Survival New findings from the American Cancer Society are offering a more hopeful picture for the millions of Americans facing a cancer diagnosis each year. The latest data suggest that seven in ten people diagnosed with cancer now survive at least five years, marking a notable increase in long-term survival. This…
-
americans living longer after cancer diagnosis: rising survival rates offer hope
Uplifting Trends in American Cancer Survival New findings about cancer survival in the United States are offering renewed hope to millions. Recent data from the American Cancer Society show that seven out of every ten Americans diagnosed with cancer now survive for at least five years. That figure represents a meaningful improvement in cancer outcomes…
-
New Diagnostic Device Signals a Turning Point in Australia’s Deadliest Cancer Treatments
Australia’s Deadliest Cancer Faces a New Turning Point Pancreatic cancer remains one of Australia’s most lethal diseases, with late diagnoses often limiting treatment options and survival. A new diagnostic device, currently under clinical evaluation, promises to shift this trajectory by enabling earlier detection and more personalized treatment decisions. The device merges advanced biomarkers with imaging…
-
NDL2 Nuclear PD-L1 Degrader Shows Promising Preclinical Data for Immunotherapy Resistance
Overview Kazia Therapeutics has announced compelling preclinical and translational data for NDL2, its nuclear PD-L1 degrader. The findings suggest that targeting nuclear PD-L1 could overcome immunotherapy resistance and curb metastatic progression in certain solid tumors. This research positions NDL2 as a potentially transformative approach in cancer immunotherapy, addressing previously unrecognized drivers of disease advancement. What…
-
Kazia Therapeutics Unveils Compelling NDL2 Data on Nuclear PD-L1 Driving Immunotherapy Resistance
Kazia Therapeutics Reveals Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) Kazia Therapeutics, a leader in oncology-focused drug development, announced new preclinical and translational data supporting the potential of its Nuclear PD-L1 Degrader 2 (NDL2). The data illuminate nuclear PD-L1 as a previously underappreciated driver of immunotherapy resistance and metastatic progression, offering a…
-
Six Medicines Recommended for EU Approval by CHMP (Jan 2026 Meeting)
Overview: CHMP’s January 2026 meeting highlights The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) released its key conclusions from the January 2026 meeting, announcing the recommendation of six new medicines for marketing authorization in the European Union. The decisions illustrate the EMA’s ongoing effort to expand access to innovative therapies while…
-
CHMP January 2026 Highlights: Six Medicines Recommended for Approval
Overview of CHMP January 2026 Highlights The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded its January 26–29, 2026 meeting with a landmark outcome: six medicines were recommended for approval. This decision, if adopted by the European Commission, would bring new therapies to patients across a range of conditions. The CHMP…
-
CHMP January 2026 Highlights: Six Medicines Recommended for Approval by EMA
Overview: CHMP’s January 2026 decision highlights The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded its January 2026 session by recommending six medicines for marketing authorization in the European Union. This marks a significant moment for patients awaiting new therapies, as well as for the biotech and pharmaceutical industries focused on…
-
NHS Launches Unified End-to-End Lung Cancer Diagnostic Pathway with Optellum
Overview: A landmark NHS initiative with Optellum The National Health Service (NHS) has unveiled a groundbreaking, single end-to-end diagnostic pathway for lung cancer, developed in collaboration with Optellum, a leader in AI-powered lung cancer risk assessment. This initiative seeks to streamline every step from initial referral through to definitive diagnosis and treatment planning, harnessing Optellum’s…
-
Ascletis Reports Positive Topline Results for Denifanstat (ASC40) in Phase III Open-Label Trial
Summary of Positive topline results for denifanstat (ASC40) Ascletis announced favorable topline results from its Phase III open-label study evaluating denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor. The company highlighted favorable safety and tolerability, with efficacy signals aligning with prior data and reinforcing the potential of ASC40 as a transformative therapeutic option.…